- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04386174
Brain Activity in People With Chronic Neuropathic Pain and Spinal Cord Injury
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Neuropathic pain is a kind of pain that is caused by a disruption of the nervous system. Neuropathic pain is common among people with spinal cord injury (SCI), is often severe, and can interfere significantly with daily life. Current treatments do not eliminate neuropathic pain for most individuals. Therefore, it is important to identify other strategies that enable people with SCI to exert more control over their pain.
The purpose of this research study is to examine patterns of brain activity in people with SCI while they perform different thinking tasks. This study will help researchers understand how patterns of brain activity change during these tasks and how these tasks affect pain severity and unpleasantness. The information we learn in this study will help us create new treatment options to help people with SCI to manage their chronic neuropathic pain.
The study will take place over 2 days, separated by 1-3 weeks or so, depending on scheduling of study activities. The study should take approximately 1 hour on the first day (for a telephone interview), and up to 7.5 hours on the second day (for a visit to Kessler for functional magnetic resonance imaging, or fMRI).
In this study, participants will be asked to respond to a series of questions relating to their physical health, mental health, and pain history. The researchers may also review their medical records if needed to determine if it is safe for them to have an MRI. Those who qualify will visit Kessler and will be introduced to different thinking strategies that can be used to try to change the activity in the brain in areas that relate to the experience of pain. Participants will undergo 3 separate fMRI sessions. During the first session, the researchers will locate a pain-related region of the brain from which to gather information about brain activity. In the second and third sessions, the researchers will use fMRI to measure the activity in a pain-related region of the brain while the participant tries out different thinking strategies. While participants practice use of these strategies, they will be shown information about brain activity and will be asked to use this information as they try to become better at using the strategies. The researchers will also ask participants whether the experience of their pain (severity and unpleasantness) changed while they practiced these strategies.
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Jeanne M. Zanca, PhD, MPT
- Phone Number: 973-324-3558
- Email: jzanca@kesslerfoundation.org
Study Locations
-
-
New Jersey
-
West Orange, New Jersey, United States, 07052
- Recruiting
- Kessler Foundation
-
Contact:
- Jeanne M Zanca, PhD, MPT
- Phone Number: 973-324-3558
- Email: jzanca@kesslerfoundation.org
-
Principal Investigator:
- Jeanne M Zanca, PhD, MPT
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 or over
- Right-handed
- Complete or incomplete chronic (>1 year) SCI classified as having a neurological level of C4 or below
- Chronic (≥3 month history) at- or below-level neuropathic pain
- Neuropathic pain of moderate or greater intensity (average intensity over the last week of ≥4 on an 11-point Numeric Rating Scale (NRS), where 0 = "no pain" and 10 = "worst pain imaginable")
- Neuropathic pain that is constant (present 7 days/week, 24 hours/day)
- Using a stable pain treatment regimen (not actively in process of starting a new pain treatment or changing dosage of an existing treatment)
- Able to understand verbal and written English
- Able and willing to comply with the study protocol, including availability for scheduled study procedures
Exclusion Criteria:
- Current non-neuropathic pain of severe intensity (average intensity over the last week of ≥7 on an 11-point NRS, where 0 = "no pain" and 10 = "worst pain imaginable")
- SCI due to malignancy
- Cognitive impairment that could interfere with learning (Mini-Mental State Exam score of <24)
- Current sacral, coccyx, or heel pressure injury
- Claustrophobia or fear of confined spaces
- Presence of any non-MRI compatible material in the body such as pacemakers or other implanted electrical devices, brain stimulators, particular types of dental implants, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves, and internal hearing aids [cochlear implants]), permanent eyeliner, implanted delivery pumps, or shrapnel fragments
- If female, currently pregnant
- Required use of non-MRI-compatible orthoses or devices (braces, ventilators, etc.)
- Current or past history of work as a welder or metal worker (because of possible small metal fragments in the eye of which they may be unaware)
- Inability to tolerate a supine position
- History (via self-report) of significant, uncontrollable spasticity while lying in supine position
- Progressive conditions that impact physical or cognitive functioning (metastatic cancer, multiple sclerosis, Parkinson Disease, Alzheimer's disease, etc.)
- History of traumatic brain injury
- Diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder
- History of substance abuse in the past six months
- Lack of intact sensation in the anterior shoulder (where stimuli will be applied during study procedures)
- Any other condition that would, in the opinion of the investigators, pose increased risk to the subject or affect the quality of data collected
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Group A
Participants will be shown information about brain activity while trying different thinking strategies to change their experience of pain.
Both groups will be shown brain activity, but the source of the brain activity information will differ between the groups.
|
Information about activity in pain-related regions of the brain will be shown to participants to determine if receiving this information is helpful in learning different thinking strategies (such as shifting attention, imagery, mantra meditation, etc.) that may help people with SCI change their experience of neuropathic pain.
|
|
Other: Group B
Participants will be shown information about brain activity while trying different thinking strategies to change their experience of pain.
Both groups will be shown brain activity, but the source of the brain activity information will differ between the groups.
|
Information about activity in pain-related regions of the brain will be shown to participants to determine if receiving this information is helpful in learning different thinking strategies (such as shifting attention, imagery, mantra meditation, etc.) that may help people with SCI change their experience of neuropathic pain.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brain activity
Time Frame: Immediately post-training session (1 day)
|
Change in brain activity, as measured by Blood Oxygen Level Dependent (BOLD) signal
|
Immediately post-training session (1 day)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Intensity
Time Frame: Immediately post-training session (1 day)
|
Intensity of pain rated on a 0-10 Numeric Rating Scale ranging from 0 = no pain to 10 = worst pain imaginable
|
Immediately post-training session (1 day)
|
|
Pain Unpleasantness
Time Frame: Immediately post-training session (1 day)
|
Degree to which pain is unpleasant, rated on a 0-10 Numeric Rating Scale where 0 = not unpleasant at all to 10 = extremely unpleasant
|
Immediately post-training session (1 day)
|
|
Exit Interview
Time Frame: Immediately post-training session (1 day)
|
Participants will be asked questions in a semi-structured interview to learn about their experiences trying to use the information on brain activity to help them learn strategies to self-manage pain.
|
Immediately post-training session (1 day)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R-1057-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuropathic Pain
-
Unity Health TorontoRecruitingChronic Neuropathic PainCanada
-
University Hospital, Clermont-FerrandFondation ApicilCompletedNeuropathic Traumatic Pain | Pain NRS ≥ 4 | Peripheral Neuropathic Pain | Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia (PHN) | Chemotherapy Induced Neuropathic Pain | Diabetic Peripheral Neuropathic Pain (DPN) | HIV-related Neuropathic Pain (HIV)Colombia, Mexico, Ecuador, Peru, Venezuela
-
Pontificia Universidad Catolica de ChileNot yet recruiting
-
Poitiers University HospitalRecruitingChronic Neuropathic PainFrance
-
Eli Lilly and CompanyRecruitingDiabetic Peripheral Neuropathic PainUnited States, Puerto Rico
-
Hospital Ambroise Paré ParisNot yet recruitingChronic Neuropathic PainFrance
-
Shandong Suncadia Medicine Co., Ltd.RecruitingDiabetic Peripheral Neuropathic PainChina
-
Shanghai Yidian Pharmaceutical Technology Development...Not yet recruitingDiabetic Peripheral Neuropathic Pain
-
Ente Ospedaliero Ospedali GallieraCompletedNeuropathic Pain in CancerItaly
Clinical Trials on Neurofeedback
-
Kowloon Hospital, Hong KongChinese University of Hong KongCompletedStroke | Cognitive ImpairmentHong Kong
-
University of Rhode IslandCompletedNeurofeedbackUnited States
-
University of OxfordWellcome TrustTerminated
-
Leiden University Medical CenterCompletedElevated EEG Theta/Beta Ratio
-
ETH ZurichSwiss Epilepsy Centre - Klinik LenggRecruitingHealth, Subjective | Epilepsy, Temporal Lobe | Psychogenic SeizureSwitzerland
-
Laureate Institute for Brain Research, Inc.National Institute of General Medical Sciences (NIGMS)TerminatedDepressive Disorder, MajorUnited States
-
PD Dr. med. Margret Hund-GeorgiadisSwiss Tropical & Public Health Institute; Rehab BaselCompleted
-
Tel-Aviv Sourasky Medical CenterUnknown
-
National Cheng-Kung University HospitalMinistry of Science and Technology, TaiwanCompletedHIV Infections | Poor Quality SleepTaiwan
-
Kymberly YoungNational Institute of Mental Health (NIMH)Completed